Weekender: A first-of-its-kind Alzheimer's drug raises heavy questions around who will and won't get it

Signup | Forward Weekender June​ 12,​ 2021 | A roundup of this week's most read stories

BROUGHT TO YOU BY — AbbVie Value of Expertise in Aseptic Fill Finish Mitigate the risk associated with aseptic fill finish manufacturing of biologics by partnering with a CMO demonstrating proven expertise in all aspects of biologics production. Learn more.   Your opinion matters. We've officially kicked off our third annual BioPharma Dive reader survey and we want to hear from you. The feedback you provide will directly inform the journalism you see in the newsletter and on our site. The survey should take about five minutes to complete and will help us serve you better. Plus, all respondents will be entered to win a $200 gift card of your choice. Take the survey If you've already completed the survey, thank you. We look forward to reviewing your responses. Thanks again for reading, supporting, and trusting our publications. Sean Griffey CEO Industry Dive Twitter | Email Deep Dive A first-of-its-kind Alzheimer's drug raises heavy questions around who will and won't get it Biogen priced its newly approved medicine Aduhelm at an average cost of $56,000 a year, adding affordability to other barriers patients may face.  Novo keeps price in line with FDA approval of second obesity shot Wegovy, a weekly drug, joins daily Saxenda in the pharma's portfolio, which could soon be under pressure from an experimental Lilly medicine. ASCO21: An immunotherapy debate, an NK cell question and the next precision drugs Moving immunotherapy to earlier lines of treatment holds promise but, at ASCO, sparked debate, too. Fate Therapeutics, meanwhile, renewed its case for natural killer cell therapy.  Sponsored Content by Cambridge Cognition Enhancing clinical trial success for pro-cognitive drugs in schizophrenia Discover how to overcome the barriers in patient recruitment, trial design and outcome measure selection for successful pro-cognitive trials. Read eBook. Bristol Myers says CAR-T therapy beat chemo, transplant in lymphoma study The results could help support taking CAR-T therapy into earlier lines of cancer treatment, a long-held goal for the complex cellular drugs.  The FDA approved Biogen's Alzheimer's drug. The company now has years to confirm it works. Officially, Biogen has until 2029 to complete a study confirming Aduhelm's benefit. But the agency says it hopes to push the drugmaker to finish faster. Biogen Alzheimer's approval could open the door for similar drugs Approval of Aduhelm sets a precedent that could enable some drugs, like Eli Lilly's drug donanemab, to advance quickly and cause other previously sidelined ones to get a second look. Recommended For You Improve your recommendations: click here to update your profile. Deep Dive In historic move, FDA approves a closely watched and controversial Alzheimer's drug With the decision, the agency cleared the way for what many predict will become a lucrative and sought-after option — though fierce debate continues over whether Biogen's aducanumab actually benefits patients' daily lives. Featured Resources FROM: Regulatory Affairs Professionals Society Strengthen Your Regulatory Knowledge Grow your knowledge: enroll in a regulatory affairs certificate program for pharmaceuticals Advance your regulatory career: earn a dual certificate in pharmaceuticals and medical devices NEW! International Combination Products, hot off the press From Our Library Trendline Behind the scenes of gene therapy manufacturing Trendline What you need to know about oncology's research boom View all resources Best of What We're Reading POLITICO Controversial drug approval stokes concern about lack of a permanent FDA chief Associated Press US extends expiration dates for J&J COVID vaccine by 6 weeks STAT Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s Kaiser Health News Change to Gilead Assistance Program Threatens PrEP Access, HIV Advocates Say The Wall Street Journal U.S. to Donate 500 Million Covid-19 Vaccine Doses to Lower-Income Countries Bloomberg Biogen Faces Democrats' Ire Over Price Tag for Alzheimer's Drug Suggest a story we should read Upcoming Event Overcoming Challenges in Bringing Precision Medicine Therapies to Market June 29, 2021 - June 29, 2021 | Webinar 2pm ET Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip